Drug developer Biocad received approval for its rituximab biosimilar, BCD-020 (Acellbia) in Russia in 2014, and since that time, the drug has been launched in Russia and in multiple other markets around the world. While Biocad has not specified whether it plans to pursue regulatory approval for the biosimilar in the European Union, the company has announced ambitions to enter the EU market with some of its products, and researchers have published new data for the biosimilar in both oncology and rheumatology indications.
Drug developer Biocad received approval for its rituximab biosimilar, BCD-020 (Acellbia) in Russia in 2014, and since that time, the drug has been launched in Russia and in multiple other markets around the world. While Biocad has not specified whether it plans to pursue regulatory approval for the biosimilar in the European Union, the company has announced ambitions to enter the EU market with some of its products, and researchers have published new data for the biosimilar in both oncology and rheumatology indications.
Writing in Hematological Oncology, a team of authors reported on an international, multicenter trial conducted among 174 patients with indolent lymphomas who had no previous biologic treatment for their disease.1 In total, 89 patients received the biosimilar at a dose of 375 mg/m2 for 4 weeks, and 85 patients received the same dose of the reference drug.
The primary outcome was overall response rate (ORR) at day 50, and the prespecified equivalence margin was —20% to 20% for the 95% confidence interval (CI) for the difference in ORR.
The ORR at day 50 was 44.71% in the biosimilar arm and 41.89% in the reference arm. The 95% CI for the difference in ORR was —12.62% to 18.24%, which fell within the prespecified equivalence margin.
Adverse events (AEs) were reported in 68.54% of the biosimilar group and 69.41% of the reference group, respectively, and no unexpected AEs were reported. Antidrug antibodies were detected in 2 patients, both in the reference arm, write the authors.
Researchers have also recently published data for the biosimilar used in a low dose in the treatment of rheumatoid arthritis (RA) in routine clinical practice.2
In the study, 20 patients with RA who were taking concomitant methotrexate were given a low-dose (600 mg) of the biosimilar on day 1 and day 15 as a first-line biologic. At week 24, 75%, 45%, and 15% of patients met American College of Rheumatology criteria for 20%, 50%, and 70% improvement, respectively.
In total, 15% of patients experienced mild infusion-related reactions. No patients had serious AEs.
Finally, another research team reported on the impact of the biosimilar versus the reference product in terms of biomarkers in patients in RA.3
In the study, 54 patients with RA were included. A total of 34 patients were treated with 2 infusions of the reference rituximab at a dose of either 500 mg or 1000 mg with concomitant glucocorticoids and disease-modifying antirheumatic drugs (DMARDs). Twenty patients were given 2 infusions of the biosimilar at a dose of 600 mg together with DMARDs and glucocorticoids.
In both treatment groups, there were decreases in erythrocyte sedimentation rate, levels of C-reactive protein, rheumatoid factors, and mutated citrullinated vimentin at weeks 12 and 24. Depletion of CD19-positive B cells was achieved at week 12 in all patients, and B cells increased at week 24.
According to the authors, the biosimilar and its reference have a similar effect on inflammatory and immunological biomarkers in RA.
References
1. Poddubnaya IV, Alekseev SM, Kaplanov KD, et al. Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: an international multicenter randomized trial [published online November 14, 2019]. Hematol Oncol. doi: 10.1002/hon.2693
2. Kusevich D, Avdeeva A, Rybakova V. Efficacy and safety of BCD-020 as a first-line biologic therapy in patients with active rheumatoid arthritis in clinical practice [published online April 4, 2019]. Int J Rheum Dis. doi: 10.1111/1756-185X.13533.
3. Avdeeva A, Cherkasova M, Artyuhov A, et al. Comparison of the effect of rituximab (Roche) and rituximab biosimilar—BCD-020 (Biocad) on inflammatory and immunological biomarkers in patients with rheumatoid arthritis [published online June 27, 2019]. Ann Rheum Dis. doi: 10.1136/annrheumdis-2019-eular.2748.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.